Kymera Therapeutics has been granted a patent for compounds and methods to inhibit CRBN and treat CRBN-mediated disorders. The invention involves administering specific compounds to patients for treatment. GlobalData’s report on Kymera Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Kymera Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kymera Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Kymera Therapeutics's grant share as of February 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11897882B2) outlines a method for treating CRBN-mediated disorders, diseases, or conditions in patients by administering a compound of formula I-d. The method specifically targets proliferative disorders, including hematological cancers such as leukemia and lymphomas. The patent covers a wide range of leukemia subtypes, lymphoma variations, and other related conditions, offering a comprehensive approach to treating these diseases effectively.

Moreover, the patent extends its application to neurological disorders like Alzheimer's disease and conditions associated with transplantation, such as graft-versus-host disease. The compound's formula and structure are detailed in the claims, specifying the chemical composition required for the treatment method. Additionally, the patent emphasizes the inclusion of the compound in pharmaceutical compositions with suitable carriers, adjuvants, or vehicles to ensure optimal delivery and efficacy. Overall, the patent provides a detailed and structured approach to treating a variety of CRBN-mediated disorders, offering a promising avenue for patients suffering from these conditions.

To know more about GlobalData’s detailed insights on Kymera Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies